SLC5A2 and type 2 diabetes mellitus: A meta-analysis of ten randomized controlled trials of a total of 573 participants with T2DM and MASLD supports that SGLT2 inhibitors are superior over other antihyperglycemic drugs used in these RCTs in improving serum aminotransferases levels, hepatic fibrosis and lowering liver fat and body weight [183].